Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major

Stacey, Katryn J. and Blackwell, Jenefer M. (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infection and Immunity, 67 8: 3719-3726.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ308476_OA.pdf Full text (open access) application/pdf 139.08KB 0
Author Stacey, Katryn J.
Blackwell, Jenefer M.
Title Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
Formatted title
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
Journal name Infection and Immunity
ISSN 1098-5522
Publication date 1999-08
Sub-type Article (original research)
Open Access Status File (Publisher version)
Volume 67
Issue 8
Start page 3719
End page 3726
Total pages 8
Place of publication Washington, DC, United States
Publisher American Society for Microbiology
Language eng
Abstract Oligodeoxynucleotides (ODN) which contain immunostimulatory CG motifs (CpG ODN) can promote T helper 1 (Th1) responses, an adjuvant activity that is desirable for vaccination against leishmaniasis. To test this, susceptible BALB/c mice were vaccinated with soluble leishmanial antigen (SLA) with or without CpG ODN as adjuvant and then challenged with Leishmania major metacyclic promastigotes. CpG ODN alone gave partial protection when injected up to 5 weeks prior to infection, and longer if the ODN was bound to alum. To demonstrate an antigen-specific adjuvant effect, a minimum of 6 weeks between vaccination and infection was required. Subcutaneous administration of SLA alone, SLA plus alum, or SLA plus non-CpG ODN resulted in exacerbated disease compared to unvaccinated mice. Mice receiving SLA plus CpG ODN showed a highly significant (P < 5 × 10−5) reduction in swelling compared to SLA-vaccinated mice and enhanced survival compared to unvaccinated mice. The modulation of the response to SLA by CpG ODN was maintained even when mice were infected 6 months after vaccination. CpG ODN was not an effective adjuvant for antibody production in response to SLA unless given together with alum, when it promoted production of immunoglobulin G2a, a Th1-associated isotype. Our results suggest that with an appropriate antigen, CpG ODN would provide a stable, cost-effective adjuvant for use in vaccination against leishmaniasis.
Keyword Necrosis-Factor-Alpha
Th1 Immune-Response
T-cell responses
Bacterial Dna
Cutaneous Leishmaniasis
Protective immunity
Prophylactic immunization
Murine model
Balb/c mice
Tropica infection
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Chemistry and Molecular Biosciences
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 113 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Fri, 06 Sep 2013, 17:05:27 EST by Dr Katryn Stacey on behalf of School of Chemistry & Molecular Biosciences